Cytokine disbalance in common human cancers (Q37822074)

23 August 2017

1 reference

title

Cytokine disbalance in common human cancers (English)

1 reference

23 August 2017

Zoran Culig

1 reference

23 August 2017

language of work or name

English

0 references

publication date

15 December 2010

1 reference

full work available at URL

23 August 2017

1 reference

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0167488910003204?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

https://api.elsevier.com/content/article/PII:S0167488910003204?httpAccept=text/plain

20 November 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Biochimica et Biophysica Acta

20 November 2024

published in

1 reference

23 August 2017

volume

1813

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

308-314

1 reference

Interleukin-6 regulation of prostate cancer cell growth

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Paradoxical roles of IL-4 in tumor immunity

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

The interleukin-8 pathway in cancer.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6: a candidate mediator of human prostate cancer morbidity

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 is an autocrine growth factor in human prostate cancer.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interfering with inflammation: a new strategy to block breast cancer self-renewal and progression?

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Circulating interleukin-6 predicts survival in patients with metastatic breast cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Autocrine IL-6 signaling: a key event in tumorigenesis?

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Mechanisms underlying differential expression of interleukin-8 in breast cancer cells.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Inflammation and cancer: IL-6 and STAT3 complete the link.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

IL-6 signaling promotes tumor growth in colorectal cancer

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Survivin is regulated by interleukin-4 in colon cancer stem cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Epithelial interleukin-4 receptor expression promotes colon tumor growth

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Crucial role of interleukin-4 in the survival of colon cancer stem cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Leptin receptor-related immune response in colorectal tumors: the role of colonocytes and interleukin-8.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Cancer cell-derived IL-1alpha induces IL-8 release in endothelial cells

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes

20 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBAMCR.2010.12.010

20 November 2024

Identifiers

DOI

1 reference

23 August 2017

1 reference